# Allo HSCT Using RIC for Hematological Diseases

> **NCT02661035** · PHASE2 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 156 (actual)

## Conditions studied

- Acute Myelogenous Leukemia
- Acute Lymphocytic Leukemia
- Chronic Myelogenous Leukemia
- Plasma Cell Leukemia
- Myelodysplastic Syndromes
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- B-Cell Lymphoma
- Follicular Lymphoma
- Lymphoplasmacytic Lymphoma
- Mantle-Cell Lymphoma
- Prolymphocytic Leukemia
- Lymphoblastic Lymphoma
- Burkitt's Lymphoma
- Non-Hodgkin's Lymphoma
- Multiple Myeloma
- Myeloproliferative Syndromes
- Hematological Diseases

## Interventions

- **DRUG:** Allopurinol
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** ATG
- **RADIATION:** TBI
- **DRUG:** Tacrolimus
- **DRUG:** MMF
- **BIOLOGICAL:** Peripheral Blood Stem Cells
- **BIOLOGICAL:** Related or Unrelated Bone Marrow Cells

## Key facts

- **NCT ID:** NCT02661035
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-09
- **Primary completion:** 2023-04-17
- **Final completion:** 2023-05-29
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02661035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02661035, "Allo HSCT Using RIC for Hematological Diseases". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02661035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*